Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
23 mars 2023 07h55 HE
|
Evaxion Biotech
Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy This potentially enables treatment for patients with cold tumors, normally unresponsive to...
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
14 mars 2023 16h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
$120+ Billion Worldwide Immuno-Oncology Drugs Industry to 2032: Rising Number of Cancer Cases Drives the Market
13 mars 2023 12h33 HE
|
Research and Markets
Dublin, March 13, 2023 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. This report provides strategists,...
2023 Annual Next-Gen Immuno-Oncology Congress: Latest Updates in ADC's, mAb, BsAbs, Immune Checkpoint Inhibitors, and Cellular Therapy (Boston, MA, United States - June 22-23, 2023)
09 mars 2023 09h18 HE
|
Research and Markets
Dublin, March 09, 2023 (GLOBE NEWSWIRE) -- The "6th Annual Next-Gen Immuno-Oncology Conference" conference has been added to ResearchAndMarkets.com's offering. The 6th Annual Next Gen...
GeoVax Announces Decisive Progress in Establishing High-Capacity, Continuous Cell Line System to Manufacture MVA-based Vaccines
08 févr. 2023 09h00 HE
|
GeoVax, Inc.
Focused on Providing Rapid Response to Combat Emerging Infectious Threats ATLANTA, GA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
08 févr. 2023 06h30 HE
|
Evaxion Biotech
COPENHAGEN, Denmark and HENNIGSDORF, Germany, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing...
GeoVax Expands Gedeptin® Clinical Research for Advanced Head and Neck Cancers
07 févr. 2023 09h00 HE
|
GeoVax, Inc.
Phase 1/2 Trial Now Active at Stanford, Emory, and Thomas Jefferson Universities ATLANTA, GA, Feb. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028: FDA and EMA Special Drug Designations to Ignite R&D Progress
27 janv. 2023 04h58 HE
|
Research and Markets
Dublin, Jan. 27, 2023 (GLOBE NEWSWIRE) -- The "Global STAT3 Inhibitors Market & Clinical Trials Outlook 2028" report has been added to ResearchAndMarkets.com's offering. The dysregulation of...
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
19 janv. 2023 08h45 HE
|
Evaxion Biotech
COPENHAGEN, Denmark, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...